F
Faricimab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Subsidy Information and Financing Scheme
Medical Assistance Fund
Active ingredient: Faricimab
General information
Subsidy Information and Financing Scheme
[MAF] Faricimab (Vabysmo) Injection 6 mg/0.05 mL
Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration.
Treatment of adults with visual impairment due to diabetic macular oedema.
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Aflibercept 2 mg/0.05 mL prefilled syringe and vial; and
Faricimab 6 mg/0.05 mL vial
for treating adults with visual impairment due to:
diabetic macular oedema; and
neovascular (wet) age-related macular degeneration.
Funding status
[R] Aflibercept 2 mg/0.05 mL prefilled syringe and vial are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 November 2025.
[R] Faricimab 6 mg/0.05 mL vial is recommended for inclusion on the MAF for the abovementioned indications from 1 March 2024.
[NR] MAF assistance does not apply to other formulation(s) or strengths(s) of aflibercept and faricimab for treating diabetic macular oedema or neovascular age-related macular degeneration.
16/09/2025 Aflibercept and faricimab for treating macular oedema secondary to retinal vein occlusion
The Ministry of Health’s Drug Advisory Committee has recommended aflibercept 2 mg/0.05 mL prefilled syringe and vial for treating adults with visual impairment due to macular oedema secondary to retinal vein occlusion.
The Ministry of Health’s Drug Advisory Committee has not recommended faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to macular oedema secondary to retinal vein occlusion, due to the unacceptable pricing proposal from the company.
Funding status
[R] Aflibercept 2 mg/0.05 mL prefilled syringe and vial are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.
[NR] MAF assistance does not apply to faricimab, and other formulation(s) or strengths(s) of aflibercept for the abovementioned indication.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Vabysmo Injection 6 mg/0.05 mL |
|